Vortioxetine
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Vortioxetine: From Major Depressive Disorder to Neurotic Disorder
One-Sentence Summary
Vortioxetine is a multimodal serotonergic antidepressant, and literature in this evidence pack describes it as "currently approved for the treatment of major depressive disorder (MDD)." The TxGNN model's top-ranked prediction is Neurotic Disorder, an older, broad diagnostic term overlapping with the depressive/anxiety spectrum, currently supported by only 1 clinical trial and 1 publication. A closely related candidate in the same prediction set — Neurotic Depression — is essentially synonymous with MDD under older nomenclature and carries far stronger evidence (6 clinical trials, 20 publications, multiple Phase 3 RCTs).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major Depressive Disorder (MDD) — per literature within this pack (PMID 29189941, 25016186); original_moa/original_indications fields are data gaps and not marketed in Norway, so no local license text is available |
| Predicted New Indication | Neurotic Disorder |
| TxGNN Prediction Score | 99.24% |
| Evidence Level | L3 (per pack scoring: single retrospective real-world trial, Grade C relevance + one Review, Tier 3) |
| Norway Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
The drug.original_moa field is marked as a data gap. However, literature already collected in this evidence pack (Sanchez et al. 2015, PMID 25016186) describes vortioxetine's mechanism: it is a serotonin transporter (SERT) inhibitor with additional 5-HT1A receptor agonism, 5-HT1B partial agonism, and 5-HT3/5-HT7/5-HT1D receptor antagonism, which increases serotonergic, noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic neurotransmission in brain circuits implicated in mood and cognition.
"Neurotic disorder" is a broad, largely obsolete diagnostic umbrella (ICD-9-era terminology, not part of current DSM-5 nomenclature) that spans anxiety- and depression-adjacent presentations. Mechanistically, a multimodal serotonergic agent is plausible for this spectrum, but because the term itself lacks diagnostic specificity, the supporting evidence is thin and largely indirect — this is explicitly acknowledged in the pack's own repurposing_rationale for this candidate.
Notably, four of the five predicted indications in this pack (neurotic disorder, neurotic depression, melancholia, dysthymic disorder) all sit within the same depressive/neurotic-spectrum cluster, essentially re-detecting vortioxetine's known antidepressant profile through different historical naming conventions. Among these, neurotic depression (rank 2, score 99.09%) has by far the strongest clinical evidence — six trials including multiple completed Phase 3 RCTs, and 20 publications including systematic reviews and network meta-analyses in MDD — and should be treated as the practical anchor for this signal cluster. The fifth candidate, benign paroxysmal torticollis of infancy, is a pediatric paroxysmal disorder with no supporting trials or literature and is most plausibly model noise rather than a genuine repurposing signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04446039 | N/A | Completed | 370,212 | Large real-world retrospective claims-database cohort comparing medication utilization patterns and adverse-outcome risk across commonly used antidepressants; not designed specifically around a "neurotic disorder" diagnosis, so relevance is indirect (Grade C). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31006795 | 2019 | Review | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | Case-based review of "neurotic depression" treatment, noting the advantages of combining antidepressants with cognitive behavioral therapy. |
Norway Market Information
Vortioxetine is currently not marketed in Norway (market_status: 未上市, total_licenses: 0); no authorization records are available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug-interaction data are currently unavailable in this evidence pack (DG001, marked Blocking — TFDA/Norway package insert warnings and contraindications have not yet been retrieved, which prevents entry into the S1 safety pre-assessment stage).
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked candidate, "Neurotic Disorder," is an imprecise legacy diagnostic term with only one indirect real-world trial and one case-review article — insufficient evidence to proceed on its own.
- Within the same prediction cluster, "Neurotic Depression" (L1/S3, "Proceed with Guardrails") is a far stronger, better-evidenced signal and is essentially equivalent to vortioxetine's known MDD indication under older nomenclature; it should be the priority target if this repurposing direction is pursued.
To proceed, the following is needed:
- Retrieve TFDA/Norway package insert warnings, contraindications, and DDI data (DG001, blocking) before any S1 safety assessment.
- Retrieve confirmed mechanism-of-action data from DrugBank (DG002).
- Clarify diagnostic mapping of legacy terms (neurotic disorder, neurotic depression, melancholia, dysthymic disorder) to current DSM-5/ICD-11 categories to consolidate this into a single, well-defined target indication — likely centered on "Neurotic Depression"/MDD-spectrum use.
- Treat "benign paroxysmal torticollis of infancy" as low-priority/likely noise given zero supporting trials or literature; do not advance without independent mechanistic justification.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.